Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? Article

cited authors

  • Miller, Caela R.; Chappell, Nicole P.; Sledge, Caitlin; Leath, Charles A., III; Phippen, Neil T.; Havrilesky, Laura J.; Barnett, Jason C.

authors

Publication Date

  • January 1, 2017

webpage

published in

category

keywords

  • Actinomycin D
  • Cost-effectiveness
  • GOG0174
  • Low risk gestational trophoblastic neoplasia
  • Methotrexate

start page

  • 125

end page

  • 129

volume

  • 144

issue

  • 1